Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.
Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
Where Today's News Shapes Tomorrow
